Multi-center Study to Investigate the Effects of Citrasate® on Heparin N Requirements During Hemodialysis Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-12-31

Study Completion Date

2010-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether the use of Citrasate®, citric acid dialysate enables the reduction of the heparin N (anticoagulant) dose in patients undergoing hemodialysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effectiveness and Safety of 4% Sodium Citrate as a Lock Solution in Central Venous Hemodialysis Catheter

NCT05188339

Central Venous Catheter Thrombosis Renal Dialysis

UNKNOWN PHASE2/PHASE3

Citrate Pharmacokinetics and Regional Citrate Anticoagulation in CRRT

NCT00948558

Acute Kidney Failure With or Without: MODS Sepsis +1 more

UNKNOWN

Citrate Anticoagulation for Postdilution Hemofiltration

NCT03969966

Acute Kidney Injury Critical Illness

UNKNOWN

Study Using Citrate to Replace Heparin in Babies Requiring Extracorporeal Membrane Oxygenation (ECMO)

NCT00968565

Heart Defects, Congenital Respiratory Insufficiency

COMPLETED EARLY_PHASE1

Effect of Citrate Dialysate on Vascular Calcification

NCT04956120

Vascular Calcification

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

During hemodialysis, waste products are removed from the blood by diffusion across the dialyzer membrane into an electrolyte solution known as dialysate. Dialysate is produced from acid concentrate, bicarbonate solution and water using a three stream proportioning system that mixes the acid concentrate, bicarbonate and water to produce the final dialysate. Patients are typically anticoagulated with heparin during dialysis to prevent blood from clotting in the extracorpoeial circuit. Heparin use is associated with significant risks including the possibility of bleeding, heparin induced thrombocytopenia (HIT) and contamination. For these reasons, the possibility of reducing heparin dose while maintaining HD adequacy is clinically attractive. Citrasate® is an FDA approved acid concentrate that contains citric acid (citrate) rather than acetic acid (acetate) which is traditionally used in acid concentrate. Citrate in higher concentrations is also a known anticoagulant. We are therefore conducting this study to determine whether the use of Citrasate, citric acid dialysate enables the reduction of the heparin requirements in patients undergoing hemodialysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Dialysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Citrasate and heparin reduction

Sequential hemodialysis treatment study in which all enrollees move through four (4) separate treatment phases. Results from the separate phases will be compared to standard bicarbonate dialysis with standard does of heparin.

Heparin N reduction

Intervention Type DRUG

Dialysis with Citrasate, acid concentrate plus 100% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 80% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 66.7% of patient's standard heparin N dose.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Heparin N reduction

Dialysis with Citrasate, acid concentrate plus 100% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 80% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 66.7% of patient's standard heparin N dose.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Citrasate® Heparin N

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is capable of giving informed consent, or has an acceptable surrogate capable of giving consent on the subject's behalf.
* ESRD maintained on thrice weekly HD
* Stable Heparin prescription (Heparin dose) for the previous 4 weeks
* Dialyzed using bolus heparin anticoagulation with dose \>/= 2000 units per treatment
* Hgb \>/= 9.5 prior to study start
* eKt/V \>/= 1.0 (or spKt/V \>/= 1.2) in the monthly lab work prior to study start

Exclusion Criteria

* Any laboratory abnormality, medical condition or psychiatric disorder which in the opinion of the investigator would put the subject's disease management at risk or may result in the subject being unable to comply with study requirements
* Patient is maintained on Coumadin therapy or LMW heparin
* Known history of HIT, coagulopathy or any other bleeding and/or thrombotic disorders
* Patients dialyzed with \< 2000 units of Heparin per treatment
* Dialyzed without heparin
* Known pregnancy
* Dialyzed with reuse of hemodialyzers
* Documented clotted dialyzer or dialysis lines in last 30 days (1 month) requiring changing dialyzer, bloodlines or terminating treatment
* Randomized in a clinical trial involving anticoagulation in the last 30 days

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No